Bedrijf laden
Just reported
Q3 2026 results
From Immunitybio's results release of 9 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 48,8M
+52% y/y
-4,7% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ -0,18
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -78M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Immunitybio is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 47,6BA+
EXELExelixis, Inc.US$ 16,8BA+
JAZZJazz Pharmaceuticals plcUS$ 15,5BA
TECHBIO-Techne CorpUS$ 11,4BA+
HALOHalozyme Therapeutics, Inc.US$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 okt 2026CAGraded C, now A
Gebouwd uit de eigen deponeringen van Immunitybio, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
